European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Complexities of managing heart failure

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

10' education - May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague

Similar association of smoking and its cessation with HFpEF and HFrEF

Literature - June 15, 2022 - Ding N, et al. - J Am Coll Cardiol. 2022

Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.

Improved guideline-directed therapy prescription for HFrEF with electronic health record alert

News - Apr. 19, 2022

ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

Novel potassium binder maintains lower K+ levels in HFrEF

News - Apr. 16, 2022

ACC 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium (K+) compared to placebo, but also in a lower risk of hyperkalemia events and in enablement of RAASi therapy in HFrEF patients on RAASi therapy.

Reduced sodium intake in HF does not lower clinical events

News - Apr. 15, 2022

ACC 2022 Although a reduction in sodium intake in HF patients did not result in a reduction of all-cause mortality of CV hospitalization compared to usual care, patient-centered outcomes were improved.

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD
What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

ACC 2022 What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD
Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz
**ACC 2022** The SODIUM-HF trial showed that a dietary intervention to reduce sodium intake did not reduce clinical events in ambulatory patients with HF. However, sodium reduction improved quality of live and NYHA class.

ACC 2022 The SODIUM-HF trial showed that a dietary intervention to reduce sodium intake did not reduce clinical events in ambulatory patients with HF. However, sodium reduction improved quality of live and NYHA class.

Improvement of symptoms, physical function and quality of life with SGLT2i in acute HF

News - Apr. 5, 2022

ACC 2022 An analysis showed that treatment with empagliflozin in patients with acute HF resulted in clinical benefit, regardless of symptomatic impairment at baseline, and improved symptoms, physical function and quality of life.

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD
Based on results from the SODIUM-HF trial, what can you tell your patients with heart failure when they take a small amount of salt and worry about harmful effects?

ACC 2022 Based on results from the SODIUM-HF trial, what can you tell your patients with heart failure when they take a small amount of salt and worry about harmful effects?

SGLT2i approved by EC for chronic HF regardless of ejection fraction

News - Mar. 9, 2022

Empagliflozin has received approval from the European Commission for the treatment of symptomatic chronic HF across the full spectrum of LVEF.

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD
Iron deficiency is very common in HF patients, also in patients who are nonanemic. Therefore, you need to measure it and treat it, conclude Robert Mentz and Peter van der Meer.

Iron deficiency is very common in HF patients, also in patients who are nonanemic. Therefore, you need to measure it and treat it, conclude Robert Mentz and Peter van der Meer.

Increased morbidity and mortality at normal natriuretic peptide levels in HFpEF

Literature - Feb. 22, 2022 - Verbrugge FH et al. - Eur Heart J. 2022

Patients with HFpEF and normal natriuretic peptide levels display abnormalities in cardiac structure, -function, and hemodynamic parameters, as well as a higher risk for mortality or HF hospitalization compared with controls with dyspnea due to non-cardiac causes.